Gupta, Saksham
Hoffman, Samantha E.
Mehta, Neel H.
Hauser, Blake
Altshuler, Marcelle
Bernstock, Joshua D.
Smith, Timothy R.
Arnaout, Omar
Laws, Edward R.
Article History
Accepted: 31 January 2024
First Online: 12 February 2024
Declarations
:
: This research study was conducted retrospectively from data obtained for clinical purposes. There are no personal identifying details of any patients in this manuscript. For retrospective de-identified clinical research, patients are given the ability to opt-out when they are admitted at our institution. To the study authors’ best knowledge, all patients approved of use of their de-identified clinical data. This study was approved under Mass General Brigham IRB Protocol #2015P002352.
: JDB has an equity position in Treovir Inc., an oHSV clinical stage company and is a member of the POCKiT Diagnostics, Centile Bioscience, and NeuroX1 Boards of Scientific Advisors. All other authors report no disclosures or conflicts of interest related to this submission.
: The authors declare no competing interests.